© 1992 Oxford University Press
research-article |
A protective role of 1,25-dihydroxyvitamin D3 in chemically induced rat colon carcinogenesis
Gastrointestinal Research Laboratory, Gastroenterology Institute Ben-Gurion University of the Negev Beer Sheva, Israel
1Toor Institute Ben-Gurion University of the Negev Beer Sheva, Israel
2Endocrinology Laboratory, Soroka Medical Center and Clinical Biochemistry Unit, Ben-Gurion University of the Negev Beer Sheva, Israel
3To whom correspondence should be addressed
The intriguing observation has been made that 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] receptors are present in tissues not involved in calcium homeostasis and that 1,25(OH)2D3 exerts an antiproliferative, differentiation-promoting action in a variety of cancer cell lines, including cells of the large intestine. It was therefore deemed of interest to study 1,25(OH)2D3 expression and biological activity in a murine model of colon carcinogenesis. Colon carcinogenesis was induced in male rats by the sequential administration of 1,2-dimethylhydrazine dihydrochloride (DMH). Levels and binding characteristics of 1,25(OH)2D3 receptors were assessed in control and DMH-treated rat colonk mucosal high-speed supernatants. In concurrent studies, 1,25(OH)2D3 was administered (s.c, 400 ng/rat) prior to, together with and after DMH challenge and the activity of ornithine decarb-oxylase (ODC), a growth-related DMH-induced enzyme, was determined in colonic cytosols. Serum Ca2+ levels were measured concurrently. Rats submitted to identical treatment schedules were killed 10 weeks after termination of DMH administration and the whole colon was opened and examined for tumors. The results show that (i) rat colonic mucosa possesses a single class of high-affinity 1,25(OH)2D3 receptors; (ii) DMH administration provokes a marked reduction (50%) in 1,25(OH)2D3 binding sites without affecting Kd values; (iii) DMH administered concurrently with 1,25(OH)2D3 suppressed the vitamin D-induced hyper-calcemia and restored serum Ca2+ concentrations to basal levels; and (iv) 1,25(OH)2D3 delivered prior to DMH challenge obliterated the typical DMH-induced early colonic ODC activity peak and markedly reduced (50%) the number of colon adenocarcinomas. The present findings indicate that a colon-specific potent carcinogen interferes with the biological expression of 1,25(OH)2D3 and that vitamin D administered prior to a carcinogenic insult is able to reduce significantly the incidence of colon tumors, presumably acting as an antiproliferative or differentiation-promoting agent.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. D. Meier, D. J. Enepekides, B. Poirier, C. A. Bradley, J. S. Albala, and D. G. Farwell Treatment With 1-Alpha,25-Dihydroxyvitamin D3 (Vitamin D3) to Inhibit Carcinogenesis in the Hamster Buccal Pouch Model Arch Otolaryngol Head Neck Surg, November 1, 2007; 133(11): 1149 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Tangpricha, C. Spina, M. Yao, T. C. Chen, M. M. Wolfe, and M. F. Holick Vitamin D Deficiency Enhances the Growth of MC-26 Colon Cancer Xenografts in Balb/c Mice J. Nutr., October 1, 2005; 135(10): 2350 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nagpal, S. Na, and R. Rathnachalam Noncalcemic Actions of Vitamin D Receptor Ligands Endocr. Rev., August 1, 2005; 26(5): 662 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Harris and V. L. W. Go Vitamin D and Colon Carcinogenesis J. Nutr., December 1, 2004; 134(12): 3463S - 3471S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Huerta, R. W. Irwin, D. Heber, V. L. W. Go, H. P. Koeffler, M. R. Uskokovic, and D. M. Harris 1{alpha},25-(OH)2-D3 and Its Synthetic Analogue Decrease Tumor Load in the Apcmin Mouse Cancer Res., February 1, 2002; 62(3): 741 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Scaglione-Sewell, M. Bissonnette, S. Skarosi, C. Abraham, and T. A. Brasitus A Vitamin D3 Analog Induces a G1-Phase Arrest in CaCo-2 Cells by Inhibiting Cdk2 and Cdk6: Roles of Cyclin E, p21Waf1, and p27Kip1 Endocrinology, November 1, 2000; 141(11): 3931 - 3939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Díaz, C. Paraskeva, M. G. Thomas, L. Binderup, and A. Hague Apoptosis Is Induced by the Active Metabolite of Vitamin D3 and Its Analogue EB1089 in Colorectal Adenoma and Carcinoma Cells: Possible Implications for Prevention and Therapy Cancer Res., April 1, 2000; 60(8): 2304 - 2312. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Taniyama, H. Wanibuchi, E. I. Salim, Y. Yano, S. Otani, Y. Nishizawa, H. Morii, and S. Fukushima Chemopreventive effect of 24R,25-dihydroxyvitamin D3 in N,N'-dimethylhydrazine-induced rat colon carcinogenesis Carcinogenesis, February 1, 2000; 21(2): 173 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Khare, M. Bissonnette, B. Scaglione-Sewell, R. K. Wali, M. D. Sitrin, and T. A. Brasitus 1,25-Dihydroxyvitamin D3 and TPA activate phospholipase D in Caco-2 cells: role of PKC-alpha Am J Physiol Gastrointest Liver Physiol, April 1, 1999; 276(4): G993 - G1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Khare, M. Bissonnette, R. Wali, S. Skarosi, G. R. Boss, F. C. von Lintig, B. Scaglione-Sewell, M. D. Sitrin, and T. A. Brasitus 1,25-Dihydroxyvitamin D3 but not TPA activates PLD in Caco-2 cells via pp60c-src and RhoA Am J Physiol Gastrointest Liver Physiol, April 1, 1999; 276(4): G1005 - G1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liel, S. Shany, P. Smirnoff, and B. Schwartz Estrogen Increases 1,25-Dihydroxyvitamin D Receptors Expression and Bioresponse in the Rat Duodenal Mucosa Endocrinology, January 1, 1999; 140(1): 280 - 285. [Abstract] [Full Text]
|
|
|
|
 |
|
 M LANGMAN and P BOYLE Chemoprevention of colorectal cancer Gut, October 1, 1998; 43(4): 578 - 585. [Abstract] [Full Text] [PDF]
|
|